International Validation of Two Non-motor Scales in PD (NFS and SPARK)

Launched by INSEL GRUPPE AG, UNIVERSITY HOSPITAL BERN · Apr 24, 2020

Keywords

ClinConnect Summary

This clinical trial is focused on understanding non-motor symptoms in people with Parkinson's disease (PD). It aims to test two new scales, called the Neuropsychiatric Fluctuations Scale (NFS) and the Shame in PARKinson's disease (SPARK) Scale. These tools will help researchers better measure and understand symptoms that don’t involve movement, such as mood changes and feelings of shame, which can significantly impact the quality of life for those living with PD.

To take part in the study, participants need to be between 30 and 75 years old, have a confirmed diagnosis of Parkinson's disease, and be able to speak the language used in the scales. Unfortunately, individuals with PD dementia, which affects memory and thinking, cannot participate. Those who join will help validate these new scales, contributing to improved care and understanding of the non-motor aspects of Parkinson's disease. This trial is currently recruiting participants of all genders, and your involvement could make a real difference in how PD is understood and treated.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Written informed consent;
• • 2. PD, according to the MDS criteria;
• • 3. Age of participants \> 30 and \< 75 years;
• • 4. Being fluent in the language in which the scales are applied.
• Exclusion Criteria:
• • 1. Presence of PD dementia (defined as MoCA score \< 24).